疑难病杂志
疑難病雜誌
의난병잡지
JOURNAL OF DIFFICULT AND COMPLICATED CASES
2014年
10期
995-997
,共3页
殷泉忠%崔俊友%郑若龙%高春恒%易桂斌%李伟章%蔡菁%钱惠东%陈新军%陆叶%张华
慇泉忠%崔俊友%鄭若龍%高春恆%易桂斌%李偉章%蔡菁%錢惠東%陳新軍%陸葉%張華
은천충%최준우%정약룡%고춘항%역계빈%리위장%채정%전혜동%진신군%륙협%장화
重组人脑钠肽%扩张型心肌病%心力衰竭,顽固性%临床疗效
重組人腦鈉肽%擴張型心肌病%心力衰竭,頑固性%臨床療效
중조인뇌납태%확장형심기병%심력쇠갈,완고성%림상료효
Recombinant human brain natriuretic peptide%Dilated cardiomyopathy%Heart failure,refractory%Clinicaleffects
目的探讨重组人脑钠肽（rhBNP）治疗扩张型心肌病顽固性心力衰竭的临床疗效。方法50例扩张型心肌病顽固性心力衰竭患者随机分为重组人脑钠肽治疗组和米力农对照组各25例。2组均给予常规抗心力衰竭药物治疗，治疗组给予注射用rh BNP，对照组给予米力农静脉滴注。观察2组治疗后的临床疗效，心率、平均动脉压、尿量、心功能及血浆BNP水平变化。结果治疗后1周，治疗组总有效率为883．0％，明显高于对照组的64．0％，差异有统计学意义（ P ＜0．05）。治疗后24 h，2组心率明显下降（ P ＜0．05），平均动脉压明显降低（ P ＜0．05），尿量明显增加（ P ＜0．01），且治疗组心率下降、尿量增多均优于对照组（ P ＜0．05）。2组治疗后24 h血浆BNP水平较基线值明显降低（ P ＜0．01），治疗后1周治疗组的左心室射血分数（LVEF）较治疗前提高（ P ＜0．05）；血浆BNP显著降低，治疗组治疗后LVEF改善和血浆BNP降低均明显好于对照组（ P ＜0．01或P ＜0．05）。结论 rhBNP治疗扩张型心肌病顽固性心力衰竭患者疗效显著，可明显改善患者的心力衰竭症状。
目的探討重組人腦鈉肽（rhBNP）治療擴張型心肌病頑固性心力衰竭的臨床療效。方法50例擴張型心肌病頑固性心力衰竭患者隨機分為重組人腦鈉肽治療組和米力農對照組各25例。2組均給予常規抗心力衰竭藥物治療，治療組給予註射用rh BNP，對照組給予米力農靜脈滴註。觀察2組治療後的臨床療效，心率、平均動脈壓、尿量、心功能及血漿BNP水平變化。結果治療後1週，治療組總有效率為883．0％，明顯高于對照組的64．0％，差異有統計學意義（ P ＜0．05）。治療後24 h，2組心率明顯下降（ P ＜0．05），平均動脈壓明顯降低（ P ＜0．05），尿量明顯增加（ P ＜0．01），且治療組心率下降、尿量增多均優于對照組（ P ＜0．05）。2組治療後24 h血漿BNP水平較基線值明顯降低（ P ＜0．01），治療後1週治療組的左心室射血分數（LVEF）較治療前提高（ P ＜0．05）；血漿BNP顯著降低，治療組治療後LVEF改善和血漿BNP降低均明顯好于對照組（ P ＜0．01或P ＜0．05）。結論 rhBNP治療擴張型心肌病頑固性心力衰竭患者療效顯著，可明顯改善患者的心力衰竭癥狀。
목적탐토중조인뇌납태（rhBNP）치료확장형심기병완고성심력쇠갈적림상료효。방법50례확장형심기병완고성심력쇠갈환자수궤분위중조인뇌납태치료조화미력농대조조각25례。2조균급여상규항심력쇠갈약물치료，치료조급여주사용rh BNP，대조조급여미력농정맥적주。관찰2조치료후적림상료효，심솔、평균동맥압、뇨량、심공능급혈장BNP수평변화。결과치료후1주，치료조총유효솔위883．0％，명현고우대조조적64．0％，차이유통계학의의（ P ＜0．05）。치료후24 h，2조심솔명현하강（ P ＜0．05），평균동맥압명현강저（ P ＜0．05），뇨량명현증가（ P ＜0．01），차치료조심솔하강、뇨량증다균우우대조조（ P ＜0．05）。2조치료후24 h혈장BNP수평교기선치명현강저（ P ＜0．01），치료후1주치료조적좌심실사혈분수（LVEF）교치료전제고（ P ＜0．05）；혈장BNP현저강저，치료조치료후LVEF개선화혈장BNP강저균명현호우대조조（ P ＜0．01혹P ＜0．05）。결론 rhBNP치료확장형심기병완고성심력쇠갈환자료효현저，가명현개선환자적심력쇠갈증상。
Objective To explore the clinical effects of recombinant human brain natriuretic peptide (rh-BNP) in thetreatment of decompensated heart failure in patients with dilated cardiomyopathy .Methods A total of 50 patients with dilatedcardiomyopathy who suffered from decompensated heart failure were randomly divided into rh -BNP treatment group and milrinonecontrol group, 25 cases in each group.Both groups were treated with conventional drugs against heart failure .Treatmentgroup was injected rh-BNP while control group given intravenous drip of milrinone .Heart rates, mean arterial pressures, urinevolume, heart functions, plasma BNP and clinical effects of 2 groups before and after treatment were observed .Results Comparedwith before treatment in one week , the total effective rate of treatment group(88.0%)was notably higher than those ofcontrol group(64.0%),the difference was statistically significant ( P <0.05).After the treament, heart rates of treatmentgroupsconspicuously decreased in 24 hours, Treatment group were significantly lower heart rate ( P <0.05), mean arterialpressure was significantly lower ( P <0.05), significantly increased urine volume ( P <0.01).whereas urine volume distinctlyincreased.Besides, the left ventricular ejection fraction (LVEF) in one week and plasma BNP in 24 hours of 2 groupswere obviously improved after treatment , whereas the increased LVEF and the decreased plasma BNP in treatment group weresignificantly notable than those in control group ( P <0.01, P <0.05).Conclusion rh-BNP, being capable of amelioratingheart failure symptoms of patients evidently , has marked therapeutic effects in the treatment of decompensated heart failure inpatients with dilated cardiomyopathy .
